Skip to content

Phase I clinical study of Bacterial nanocellulose membranes modified with Poly-l-lisine-cholesterol

Safety study of topical application of bacterial Nanocellulose membranes with surface modification: phase 1 clinical trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
REBEC
Registry ID
RBR-4g4jkrw
Enrollment
Unknown
Registered
2023-10-02
Start date
2022-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds

Interventions

This is an experimental phase I clinical study, double-blind and randomized. Thus, the progression of a group of volunteers who will undergo the topical application of bacterial nanocellulose hydrogel
in a circular area corresponding to 4 cm2, and subsequently, a polyurethane film will be placed over the site to prevent the hydrogel from being removed during bathing, movement, or clothing use. Part
V03.175.250.100

Sponsors

Faculdade de Enfermagem - Universidade Federal de Juiz de Fora
Lead Sponsor
Faculdade de Enfermagem - Universidade Federal de Juiz de Fora
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Adults aged above 18 and below 60 years; of both sexes

Exclusion criteria

Exclusion criteria: Adults without a history of infectious or parasitic diseases, infectious processes, or allergy to the components of the formulation; without the use of antimicrobials, immunosuppressants, systemic corticosteroids, and antiallergic and anti-inflammatory drugs in the last 15 days; pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
Confirmation of the safety of topical application of bacterial nanocellulose hydrogel with Poly-L-Lysine-Cholesterol (BNC-PLC)

Secondary

MeasureTime frame
Optimization of the production of bacterial nanocellulose hydrogels incorporated with Poly-L-Lysine-Cholesterol for the purpose of topical application; absence of adverse effects and inflammatory signs from the topical application of BNC-PLC hydrogel on intact skin of healthy individuals through the execution of a Phase 1 clinical trial

Countries

Brazil

Contacts

Public ContactThiago Nascimento

Universidade Federal de Juiz de Fora

thiago.nascimento@ufjf.br+55(32)2102-3821

Outcome results

None listed

Source: REBEC (via WHO ICTRP)